RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $25.3 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $25.3 million, up 40.47% year-over-year; the trailing twelve-month figure through Dec 2025 was $83.8 million (down 14.63% YoY), and the FY2025 annual result was $25.3 million, up 40.47% from the prior year.
• Liabilities and Shareholders Equity improved to $25.3 million in Q4 2025 per RDHL's latest filing, from $18.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $220.1 million in Q1 2021 and troughed at $18.0 million in Q4 2024.
• A 5-year average of $109.5 million and a median of $157.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity jumped 53.42% in 2021, then tumbled 85.49% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $181.2 million in 2021, then declined by 12.32% to $158.9 million in 2022, then plunged by 85.49% to $23.0 million in 2023, then fell by 21.71% to $18.0 million in 2024, then surged by 40.47% to $25.3 million in 2025.
• Business Quant data shows RDHL's Liabilities and Shareholders Equity at $25.3 million in Q4 2025, $18.4 million in Q2 2025, and $18.0 million in Q4 2024.